KPV
KPV (lysine-proline-valine): FDA safety listing, the July 2026 advisory vote, why the evidence is only in mice and cells, and sport rules.
Not FDA-approved · Evidence grade D · Reviewed
Not approved by the FDA for human use. Not for human consumption. This page describes KPV only to explain its regulatory status, what has been studied and its known risks. Drawline does not recommend obtaining or using it. Disclaimer
- Under FDA review, not approvedGut and skin inflammationAdvisory vote for compounding, not approval
It is not named on the WADA Prohibited List, but no health authority has approved it for human use, so it falls under class S0 (non-approved substances), banned at all times.
Drug-tested athletes can look up any substance on Global DRO, run by national anti-doping agencies. Supplements can contain banned substances that are not on the label. Drawline does not suggest when to train or inject.
KPV (Lysine-proline-valine, alpha-MSH (11-13), KPV acetate). Synthetic tripeptide.
DNot FDA-approved. Evidence grade D: animal and lab data only.
What is KPV?
KPV is a three-amino-acid peptide, the tail end of alpha-melanocyte stimulating hormone (alpha-MSH). It is promoted for gut inflammation and skin healing. FDA notes it does not act on the melanocortin receptors that alpha-MSH uses, and its target is unknown.
Is KPV FDA-approved?
Not approved for any use. FDA placed it in September 2023 among bulk substances that may present significant safety risks in compounding (Category 2), then took it out of that category on April 22, 2026, ahead of an advisory review; HHS says neither step changed its legal status. In July 2026 an FDA advisory committee narrowly voted to recommend it for the list of substances pharmacies may compound, for wound healing and inflammatory conditions, against the advice of FDA staff. The vote is advisory. In October 2026 HHS published a draft policy that lists it among peptides it does not intend to act against when pharmacies compound them under set conditions while FDA decides through rulemaking. That is a decision not to enforce, not approval, and it can be withdrawn.
What does the evidence show for KPV?
FDA found no clinical studies or human exposure data for KPV by any route. The research is in cells and mice, such as studies in which it reduced chemically induced colitis.
What are the known risks of KPV?
FDA says it lacks important information about whether KPV would cause harm in people. Like other injected peptides, compounded or research products can carry impurities and clumps that may trigger immune reactions. Sport: it is not named on the WADA Prohibited List, but no health authority has approved it for human use, so it falls under class S0 (non-approved substances), banned at all times.
How is KPV measured?
A powder vial: enter the amount in the vial and the water added, and the calculator shows the syringe units for a prescribed dose. Products sold online as "research use only" have no assurance of identity, dose or sterility. The calculator can do the arithmetic for any vial, but it cannot tell you what is actually in one.
Sources: FDA: KPV briefing document, July 2026; FDA: bulk drug substances that may present significant safety risks; FDA: Pharmacy Compounding Advisory Committee, July 23 and 24, 2026; HHS: peptides covered by the draft enforcement discretion policy (Appendix B); Dalmasso et al., KPV reduces intestinal inflammation in mice (2008). This profile does not recommend any dose or use.
For research and educational use. Not medical advice. Regulatory status changes, so confirm the current position with FDA or a licensed professional.
Keep reading
Spot a mistake or an out-of-date fact? Report an error. We check every report against the sources.